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Chronic inflammation often precedes malignant transformation and later drives tumor progression.
Likewise, subversion of the immune system plays a role in tumor progression, with tumoral
immune escape now well recognized as a crucial hallmark of cancer. Myeloid-derived suppressor
cells (MDSC) are elevated in most individuals with cancer, where their accumulation and
suppressive activity are driven by inflammation. Thus, MDSC may define an element of the
pathogenic inflammatory processes that driven immune escape. The secreted alarmin HMGB1 is a
pro-inflammatory partner, inducer and chaperone for many pro-inflammatory molecules that
MDSC development. Therefore, in this study we examined HMGB1 as a potential regulator of
MDSC. In murine tumor systems, HMGB1 was ubiquitous in the tumor microenvironment,
activating the NF-κB signal transduction pathway in MDSC and regulating their quantity and
quality. We found that HMGB1 foments the development of MDSC from bone marrow progenitor
cells, contributing to their ability to suppress antigen-driven activation of CD4+ and CD8+ T cells.
Further, HMGB1 increased MDSC-mediated production of IL-10, enhanced crosstalk between
MDSC and macrophages and facilitated the ability of MDSC to down-regulate expression of the
naive T cell homing receptor L-selectin. Overall, our results revealed a pivotal role for HMGB1 in
the development and cancerous contributions of MDSC in cancer patients.
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Introduction
Anti-tumor immunity and immunotherapies that activate innate and/or adaptive immunity
have potential for the prevention and/or treatment of primary and metastatic cancers.
However, immunotherapies are frequently ineffective because cancer patients contain
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immunosuppressive cells. Myeloid-derived suppressor cells (MDSC) (1) are present in
virtually all patients with solid tumors and are major contributors to immune suppression.
They facilitate tumor progression through multiple immune mechanisms including the
inhibition of T and NK cell activation (2), polarization of immunity towards a tumorpromoting type 2 phenotype through their production of IL-10 (3), and by perturbing the
trafficking of naïve T cells by down-regulating L-selectin (4). MDSC also use non-immune
mechanisms to enhance tumor growth. They produce VEGF and matrix metalloproteases
that promote tumor vascularization (5) as well as invasion and metastasis (6).
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Chronic inflammation has long been associated with tumor onset and progression (7). The
role of chronic inflammation was originally attributed to its ability to foster genetic
mutations, enhance tumor cell proliferation and survival, and promote metastases. Chronic
inflammation also facilitates malignancy by inducing the accumulation and increasing the
potency of MDSC, which prevent adaptive and innate immunity from delaying tumor
progression (8). Multiple redundant pro-inflammatory molecules drive MDSC. Since the
Damage Associated Molecular Pattern molecule (DAMP) and alarmin High Mobility Group
Box Protein I (HMGB1) is pro-inflammatory and is a binding partner, inducer, and/or
chaperone for many of the pro-inflammatory molecules that drive MDSC (9), we have
studied HMGB1 as a potential regulator of MDSC. HMGB1 was originally identified as a
DNA binding protein in the nucleus. It performs multiple functions within the nucleus
including changing the conformation of DNA to allow for the binding of regulatory proteins,
facilitating the integration of transposons into DNA, and stabilizing nucleosome formation
(10). Its role as a secreted protein and an immune modulator has only been recognized
within the past 15 years (11).
We now report that in addition to many other cells, MDSC release HMGB1 and that
HMGB1 activates MDSC through NF-κB and facilitates several immune suppressive
mechanisms used by MDSC to inhibit anti-tumor immunity. HMGB1 drives the
differentiation of MDSC from bone marrow progenitor cells, enhances crosstalk between
MDSC and macrophages by increasing MDSC production of IL-10, and reduces the
expression of L-selectin on circulating T cells. Collectively, these results suggest that
HMGB1 contributes to immune suppression by inducing and activating MDSC.
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Materials and Methods
Mice
BALB/c, C57BL/6, BALB/c IL-10−/−, BALB/c TLR4−/−, BALB/c DO11.10 (TCRtransgenic for the αβ-TCR specific for OVA peptide 323-339 restricted by I-Ad) and
BALB/c clone 4 TCR-transgenic (αβ-TCR specific for influenza hemagglutinin 518-526
restricted by H-2Kd) mice were from The Jackson Laboratory (Bar Harbor, ME) and/or bred
in the UMBC animal facility. Mice <6 months of age were used for all experiments. All
animal procedures were approved by the UMBC IACUC.
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Reagents and antibodies
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Heparin sodium salt (grade IA) and ethyl pyruvate were from Sigma-Aldrich. Glycyrrhizin
(ammonium salt) was from Calbiochem. Recombinant mouse IL-6 and GMCSF were from
Biolegend. Recombinant mouse IFN-γ, HMGB1, and TNFα were from R&D Systems.
Recombinant LPS was from Difco. mAbs Gr1-APC-Cy7, Gr1-APC (RB6-8C5), CD45-PE
(30-F11), CD8-FITC (53-6.7), CD4-PE (L3T4/GK1.5), CD3-PE-Cy7 (145-2C11), CD11bPE (M1/70), CD11c-FITC (HL3), CD45R-B220-PE (RA3-6B2), CD62L-APC (MEL14), ckit-PE (CD117; ACK45), iNOS, arginase, rat IgG2b isotype, and annexin V were from BD
Biosciences. CD11b-PacB (M1/70), F4/80-PE (BM8), F4/80-PacB (BM8), rat IgG1a-APC
(RTK2758), and CD16/32 (93) were from BioLegend. CD45-TxR (MCD4517) was from
Invitrogen. Anti-mouse ADAM17 mAb was from Abcam (ab2051). Secondary for
ADAM17 antibody (goat-anti-rabbit; 554020) was from BD Biosciences. Anti-CD3 was
from Dako (clone F7.2.38). Recombinant A Box (12, 13) and 2G7 (14) were produced as
described.
Tumor inoculations, tumor measurements, 2G7, and A box treatment
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C57BL/6 mice were inoculated s.c. in the flank with 5×105 MC38 colon carcinoma cells,
1×106 B78H1 melanoma cells, or 1×106 AT3 mammary carcinoma cells (15). BALB/c mice
were inoculated in the abdominal mammary fat pad with 7×103 4T1 mammary carcinoma
cells or s.c. with 1 x 106 CT26 colon carcinoma cells. With the exception of AT3, which was
obtained from Dr. S. Abrams (Roswell Park Cancer Center) ~5 years ago, all tumor cell
lines have been in the authors’ laboratory for >15 years. Cell lines are routinely checked for
mycoplasma and early freeze-downs are preferentially used. Recombinant A box
(300μg/100 μl/mouse), vehicle (PBS), 2G7 mAb (5μg/200μl/mouse), or control IgG2b
antibody (MOPC 195; 5μg/200μl/mouse; Sigma Aldrich) were administered
intraperitoneally 3x/week starting when tumors were first palpable (day 7-9 post
inoculation). Tumors were measured in two perpendicular diameters every 2-3 days. Tumor
volume = πr2 where r = (diameter 1 + diameter 2)/4. Immunohistochemistry for tumorinfiltrating T cells was performed by CD3 staining of O.C.T. embedded tumors.
Tumor, MDSC, and macrophage supernatants; MEF cell lysates

NIH-PA Author Manuscript

4T1, CT26, B78H1, MC38, and AT3 tumor cells were cultured at 5×106 cells/ml in 6 well
plates in serum-free HL-1 medium at 37°C, 5% CO2. MDSC and thioglycolate-elicited
macrophages were similarly cultured except some wells contained 100ng/ml LPS.
Supernatants were harvested after 18 hours and concentrated 10x using 10kDa Centricon
filters (Millipore). Excised tumors were minced into small pieces using scissors, and placed
in 10ml of serum-free HL-1 media containing 0.8μg/ml DNase. Tumor chunks were then
dissociated into single cell suspensions using a GentleMACS Dissociator equipped with a
GentleMACS C tube and program m_tumor 01.01 (Milltenyi Biotec). Dissociated material,
including medium, was then plated in 10cm dishes and incubated at 37°C, 5% CO2 for 18
hours, after which the supernatants were collected and concentrated to 2ml using 10kDa
Centricon filters. Wild type and HMGB1-knocked out MEF cells (16) were lysed in 300μl of
M-Per buffer Mammalian Protein Extraction Reagent (Thermo Scientific) using a
GentleMACS fitted with an M tube and program protein 01.01. Lysates were centrifuged at
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10°C and 650g for 5 minutes, and the supernatants removed and centrifuged at 10°C and
160g for 15 min. Protein concentration of the supernatants was determined at 280
absorbance.
Blood MDSC
Mice were bled from the submandibular vein into 1ml of PBS containing 0.008% heparin.
RBC were removed by Gey's treatment (17). The remaining white blood cells were stained
for Gr1 and CD11b and analyzed by flow cytometry. White blood cells that were >90%
Gr1+CD11b+ were used in experiments.
MDSC- macrophage co-cultures
Peritoneal macrophage (>80%CD11b+F4/80+ cells) and MDSC co-cultures were performed
as described (3). Briefly, cells were plated at 7.5×105 MDSC and 7.5×105 macrophages/well
in 500ul of DMEM with 5% FBS, 100 ng/ml LPS, and 20 U/ml IFN-γ in 24 well plates. Cocultures were incubated at 37°C, 5% CO2 for 16-18 hrs. Supernatants were stored at −80°C
until analyzed by ELISA.
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Cytokine detection
IL-10, IL-6, IL-12, and IL-1β were measured by ELISA according to the manufacturer's
protocol (R&D Systems). Plates were read at 450 nm using a Bio-Tek synergy microplate
reader. Data are the mean ± SD of triplicate wells.
MDSC generation from bone marrow cells
MDSC were generated (18) with the following adaptations: Bone marrow was flushed
aseptically from femurs with RPMI medium using a syringe fitted with a 27g needle. RBC
were lysed with Gey's solution. Resulting cells were cultured at 37°C, 5% CO2 at 4.2 x 105
cells/2ml in 6 well plates containing RPMI medium supplemented with 10% FCS, 40 ng/ml
IL-6 and 40 ng/ml GM-CSF. After four days of culture, percent decrease in Gr1midCD11b+
cells was determined (Gr1midCD11b+ cells = 100% [(number of vehicle-treated cells –
number of inhibitor treated cells)/(number of vehicle-treated cells)]. Absolute number of
cells = (total number of cells) x % of a given cell type as determined by flow cytometry.
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T cell activation assays
T cell activation assays were performed as described (17). Briefly, splenocytes and
irradiated (2500 Rad) 4T1-induced MDSC or bone marrow generated MDSC were cocultured in 96 well plates at 105 cells/200μl/well of HL-1 media containing 1% penicillin,
1% streptomycin, 1% Glutamax, and 5 x 10-5 M β-mercaptoethanol. 14uM OVA323-339
peptide or 28 μM HA518-526 peptide was included for DO11.10 and clone 4 cells,
respectively. Wells were pulsed with 1μCi of [3H] thymidine/well on day 3, and 18 hours
later the cells were harvested. Data are expressed as cpm ± SD of triplicate cultures.
Hydrogen peroxide levels were measured as described (19).
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HMGB1 western blots and ELISA
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50 μl of equivalent quantities of concentrated supernatants of cultured tumor cells, in vivo
grown tumors, MDSC, macrophages, or 60ug of MEF cell lysates were mixed with 10 μl or
the appropriate amount of 6x sample buffer and electrophoresed on 12% SDS-PAGE gels in
SDS running buffer (BioRad) at 150 volts for 1 hour, and transferred overnight in transfer
buffer (BioRad) at 30 volts to PVDF membranes (GE Healthcare). Membranes were blocked
with 5% milk in TBST. HMGB1 was detected with anti-HMGB1 antibody (Epitomics)
(5ng/ml in 10ml of 2.5% milk/TBST) followed by goat-anti-rabbit-HRP (Millipore)
(40ng/ml in 10ml of 2.5% milk/TBST). Protein was visualized using an HRP detection kit
(Denville Scientific, Inc). HMGB1 levels were measured by ELISA according to the
manufacturer's directions (IBL International, Hamburg, Germany).
Flow cytometry
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Cells were labeled and analyzed by flow cytometry for cell surface molecules as described
(17). For bone marrow experiments, cells were first stained using the LIVE/DEAD fixable
yellow dead cell stain kit (Invitrogen) per the manufacture's protocol, followed by staining
for cell surface markers with antibodies diluted in PBS/ 2% FCS (HyClone). For NF-κB
staining of MDSC, 3×106−5×106 leukocytes/ml RPMI were incubated with/without 50
ng/ml HMGB1 for 15 minutes at 37°C, fixed and permeabilized and then stained with rabbit
mAb phospho-NF-κB p65 (Ser536; clone 93H1) and goat-anti-rabbit (Fab')2-AlexaFluor
647 (Cell Signaling, Inc.) according to the manufacturer's protocol, followed by staining for
Gr1 and CD11b. Peritoneal macrophages (5×106/5 ml DMEM) were similarly stained,
except they were rested for 2 hrs at 37°C before stimulation with 20ng/ml TNFα or
100ug/ml LPS, and subsequently incubated with Fc block (CD16/32) for 15 min., followed
by staining with NF-κB, CD11b, and F4/80 mAbs. For ADAM17 staining, 3×106−5×106
leukocytes were incubated with or without HMGB1 (50 ng/ml) or ethyl pyruvate (10mM)
for zero, two, and four hours and stained with mAb to ADAM17. For tumor-infiltrating
MDSC, solid tumors were prepared as they were for tumor supernatants, except collagenase
(300 U/ml) was included in the dissociation medium, and the resulting cells were
centrifuged through ficoll to remove dead cells. Samples were run on a Cyan ADP flow
cytometer and analyzed using Summit Software (Beckman/Coulter).
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Statistical methods
Statistical analysis of tumor growth rate was conducted utilizing the compare Growth
Curves function of the Statmod software package (http://bioinf.wehi.edu.au/software/
compareCurves). Student's t test was used to determine statistical significance between two
sets of data. Single-factor ANOVA was used to determine statistical significance between
groups of data.

Cancer Res. Author manuscript; available in PMC 2015 October 15.

Parker et al.

Page 6

Results
NIH-PA Author Manuscript

HMGB1 is ubiquitously present in the tumor microenvironment and activates MDSC via the
NF-κB pathway
If HMGB1 is associated with the induction of MDSC, then HMGB1 will be present in the
tumor microenvironment. To test this hypothesis BALB/c-derived 4T1 mammary carcinoma
and CT26 colon carcinoma cells, and C57BL/6-derived B78H1 melanoma, MC38 colon
carcinoma, and PyMT-MMTV-derived AT3 mammary carcinoma cells were cultured in
serum free-media, and the supernatants assessed by western blot for HMGB1. Whole cell
lysates of wild type MEF cells and their HMGB1-knocked out counterparts served as
positive and negative controls, respectively. All tumors constitutively secreted HMGB1
(Fig. 1 A). Secretion of HMGB1 was confirmed and quantified by ELISA (Supplementary
Table 1).
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Since MDSC are driven by inflammation and themselves produce pro-inflammatory
mediators (8, 20), we tested MDSC for secretion of HMGB1. MDSC generated in 4T1
tumor-bearing BALB/c mice were harvested from the blood, stained for Gr1 and CD11b,
and assessed for their ability to suppress T cell activation (Fig. 1B). Greater than 90% of the
blood leukocytes were CD11b+Gr1+ and they were suppressive. We then tested MDSC for
their ability to secrete HMGB1 by culturing them overnight and assaying the supernatant for
HMGB1 by western blot and ELISA (Fig. 1C, Supplementary Table 1). Macrophages are
established producers of HMGB1 (11) and LPS is reported to increase their secretion of
HMGB1 (21). To determine if LPS similarly affects MDSC, MDSC were cultured with and
without LPS. Both LPS-treated and untreated MDSC produced more HMGB1 than
equivalent numbers of LPS-treated macrophages, demonstrating that MDSC constitutively
secrete HMGB1.
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To determine if HMGB1 is present in vivo within the tumor microenvironment, 4T1, CT26,
B78H1, MC38, and AT3 tumors of BALB/c and C57BL/6 tumor-bearing mice were
measured, and then excised and weighed. Explanted tumors were then dissociated into
single cell suspensions without disrupting cell integrity, and incubated in serum-free
medium. The resulting supernatants were assessed by western blot and ELISA for HMGB1
(Fig. 1C right-hand 5 lanes, Supplementary Table 1). All excised tumors released
HMGB1; however, the quantity of HMGB1 released did not directly correlate with tumor
burden. Since different types of tumors contain different quantities of HMGB1-producing
cells and necrotic cells (i.e. tumor cells, macrophages, MDSC, etc.), it is not unexpected that
HMGB1 levels are not proportional to tumor mass.
HMGB1 binds to multiple receptors including two receptors that are expressed by MDSC:
TLR4 (22) and Receptor for Advanced Glycation Endproducts (RAGE) (23). Signaling
through both of these receptors converges on the NF-κB signal transduction pathway. To
determine if HMGB1 activates MDSC, leukocytes from the blood of tumor-free BALB/c
mice were cultured with or without HMGB1, subsequently stained for phosphorylated NFκB (pNF-κB), and the Gr1+CD11b+ cells gated and analyzed for pNF-κB (Fig. 1D).
HMGB1-treatment caused phosphorylation of NF-κB.
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To confirm the specificity of the pNF-κB staining, macrophages from either TLR4+/+ or
TLR4−/− mice were treated with either LPS or TNFα. If the pNF-κB mAb is specific, then
TNFα will activate NF-κB in both TLR4+/+ and TLR4−/− cells since it acts via the TNFα
receptor. In contrast, NF-κB will only be activated by LPS in TLR4+/+ cells, since LPS
activates NF-κB via TLR4. TNFα activated NF-κB in both TLR4+/+ and TLR4−/− cells,
while LPS activated NF-κB in TLR4+/+, but not TLR4−/− cells, confirming the specificity of
the pNF-κB mAb (Supplementary Fig. S1).
These data indicate that HMGB1 is ubiquitously present in vivo in the tumor
microenvironment, multiple cell populations within the tumor microenvironment produce
HMGB1, MDSC contribute to the production of HMGB1, and HMGB1 activates the NF-κB
signal transduction pathway in MDSC.
HMGB1 drives the differentiation of MDSC from bone marrow progenitor cells
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Since the differentiation, accumulation, and function of MDSC are driven by inflammation
(8, 20, 24, 25), HMGB1 may regulate MDSC by either controlling their accumulation and/or
affecting their functional activities. To assess if HMGB1 affects MDSC differentiation, bone
marrow cells from the femurs of healthy BALB/c mice were cultured under conditions that
drive the differentiation of MDSC (18). The HMGB1 inhibitors ethyl pyruvate and
glycyrrhizin were included in some cultures. Ethyl pyruvate prevents extracellular secretion
of HMGB1 from activated monocytes and macrophages by blocking NF-κB signaling (26).
Glycyrrhizin prevents the binding of extracellular HMGB1 by attaching to two distinct
regions of HMGB1 (27). At the end of the four day culture period, the presence of HMGB1
was confirmed by western blot (Fig. 2A) and quantified by ELISA (Supplementary Table
1), and the absolute number of Gr1midCD11b+ cells was determined by cell counting and
flow cytometry (Fig. 2B). At the start of culture, 5.5×104 cells were Gr1midCD11b+. At the
end of the culture period the vehicle control-treated cultures contained 1.6×105
Gr1midCD11b+ cells indicating that MDSC had expanded by almost 3 fold. Both HMGB1
inhibitors significantly reduced the absolute number of MDSC (Fig. 2C, Supplementary
Table 2). The highest dose of glycyrrhizin reduced the number of Gr1midCD11b+ cells by
82%, while ethyl pyruvate reduced the number by 80%. Gr1+CD11b+ MDSC induced under
these conditions were just as suppressive as tumor-induced MDSC isolated from mice with
4T1 tumors (Fig. 2D). Glycyrrhizin and ethyl pyruvate also decreased the generation of DC
(CD11c+ cells, 43% and 67%, respectively) and macrophages (F4/80+CD11b+ cells, 66%
and 68%, respectively), consistent with published reports showing that HMGB1 also drives
the maturation of these cells (28). In contrast, B cells (B220+ cells) and T cells (CD3+ cells)
were either not affected or only minimally decreased.
To determine if inhibition of HMGB1 reduces MDSC accumulation by inhibiting the
proliferation of MDSC progenitor cells or by causing apoptosis of differentiated MDSC,
bone marrow cells and matured MDSC were vehicle or ethyl pyruvate-treated and the levels
of c-kit+ (CD117) progenitor cells and Annexin V+PI+ apoptotic cells were determined by
flow cytometry (Fig. 2E, Supplementary Fig. S2A). Ethyl pyruvate reduced the level of
progenitor cells but did not induce apoptosis as compared to vehicle treatment. These data
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indicate that HMGB1 facilitates the expansion of myeloid cells, including MDSC, from
bone marrow progenitor cells.

NIH-PA Author Manuscript

HMGB1 contributes to the ability of MDSC to suppress antigen-driven T cell activation
MDSC use multiple mechanisms to suppress anti-tumor immunity. Suppression of antigendriven T cell activation was one of the first mechanisms identified (29, 30). To determine if
HMGB1 impacts MDSC suppression of T cell activation, MDSC from 4T1 tumor-bearing
BALB/c mice were tested for their ability to prevent the proliferation of transgenic CD4+
(DO11.10) or CD8+ (Clone 4) T cells activated with cognate peptides (Fig. 3A). Increasing
concentrations of the HMGB1 inhibitor ethyl pyruvate restored T cell activation in the
presence of MDSC. Since ethyl pyruvate prevents signaling through NF-κB and T cell
activation requires NF-κB signaling (31), transgenic T cells were treated with ethyl pyruvate
to ascertain that these doses were not affecting T cell proliferation (Fig. 3B). Ethyl pyruvate
did not increase T cell activation in the absence of MDSC, demonstrating that the increase in
T cell activation seen in fig. 3A is an effect of ethyl pyruvate on MDSC and not an effect on
T cells.
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To determine how ethyl pyruvate inhibits MDSC, control and ethyl pyruvate-treated MDSC
were assayed by flow cytometry for their content of molecules that mediate T cell
suppression (arginase, iNOS, and H2O2), and for its impact on MDSC viability. Ethyl
pyruvate did not decrease arginase or iNOS levels or alter MDSC apoptosis levels
(Supplementary Fig. S2B, S2C), but modestly reduced H2O2 levels (Supplementary Fig.
S2D) as compared to vehicle-treated cells. In previous studies, another NF-κB inhibitor,
Withaferin A, also reduced the suppressive potency of MDSC (19). These results suggest
that HMGB1 contributes to MDSC-mediated T cell suppression by increasing their
expression of H2O2.
HMGB1 increases MDSC production of IL-10 and MDSC-macrophage crosstalk
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One of the mechanisms MDSC use to inhibit anti-tumor immunity is their production of
IL-10. MDSC-produced IL-10 reduces macrophage production of IL-12, thereby skewing
macrophages towards a type 2 tumor-promoting phenotype (3). Crosstalk between MDSC
and macrophages increases MDSC production of IL-10, thereby contributing to MDSC
suppression. MDSC-produced IL-10 also drives the differentiation and accumulation of T
regulatory cells (32), further increasing immune suppression. To determine if HMGB1
drives MDSC production of IL-10 or MDSC-macrophage crosstalk with respect to IL-10,
MDSC and macrophages were co-cultured with or without ethyl pyruvate and glycyrrhizin
and IL-10 production was measured (Fig. 4A). Both ethyl pyruvate and glycyrrhizin dosedependently reduced the production of IL-10 by MDSC and by mixtures of MDSC plus
macrophages. To ascertain that MDSC, rather than macrophages, are the producers of IL-10,
macrophages and MDSC from IL-10-deficient BALB/c mice were used in conjunction with
MDSC or macrophages, respectively, from wild type BALB/c mice (Fig. 4B). Only
marginal levels of IL-10 were detected in cultures containing IL-10−/− MDSC with wild
type macrophages, demonstrating that MDSC are the cells producing the IL-10. The
reduction of IL-10 is not due to reduced MDSC viability since ethyl pyruvate-treated MDSC
cultured under the crosstalk conditions (with 5% serum) are more viable than vehicle-treated
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MDSC (Supplementary Fig. S2C). These findings indicate that HMGB1 regulates MDSC
production of IL-10 and macrophage-induced increases in MDSC production of IL-10.
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MDSC also promote a type 2 immune response by down-regulating macrophage production
of IL-12 (3) and IL-6 (unpublished). To determine if HMGB1 mediates either of these
effects, MDSC and macrophages were co-cultured with or without ethyl pyruvate and
glycyrrhizin and IL-12 and IL-6 were quantified by ELISA (Fig. 5). Ethyl pyruvate and
glycyrrhizin reduced macrophage production of IL-12 and IL-6, and did not restore
production of these cytokines in MDSC-macrophage co-cultures. IL-1β, a pro-inflammatory
cytokine that is produced by MDSC and also drives the suppressive potency of MDSC (33,
34), was also assessed. Ethyl pyruvate and glycyrrhizin decreased MDSC production of
IL-1β; however, HMGB1 inhibition restored IL-1β levels in co-cultures of MDSC and
macrophages. These results indicate that HMGB1 regulates MDSC production of IL-1β
during MDSC-macrophage crosstalk; however it is not involved in MDSC-mediated downregulation of macrophage-produced IL-12 or IL-6.
Neutralization of HMGB1 delays tumor growth and reduces MDSC in tumor-bearing mice
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HMGB1 includes two functional domains: the pro-inflammatory B Box and the antiinflammatory A Box. The B Box is a RAGE agonist, while the A Box is a RAGE antagonist
(13). Although the A Box is a competitor for the B Box, the B Box of HMGB1 is dominant
in vivo (27). However, if administered in vivo as a recombinant protein, A Box neutralizes
endogenous HMGB1 (14). To determine if A Box impacts tumor progression, BALB/c and
C57BL/6 mice bearing 4T1 or MC38 tumor, respectively, were treated with A Box or
vehicle control starting when the tumors were first palpable (approximate day 7-9 after
tumor cell inoculation) (Fig. 6A). In both strains, A Box delayed tumor progression,
supporting the concept that HMGB1 facilitates tumor growth. 4T1 tumor cells were also
knocked-down by shRNA for HMGB1 (4T1/575 cells) and their tumorigenicity compared to
that of 4T1 cells transfected with an irrelevant shRNA (4T1/irrelevant) (Supplementary
Fig. S3A). The effect of HMGB1 on spontaneous metastatic disease was assessed by
treating 4T1 tumor-bearing mice with glycyrrhizin and ethyl pyruvate and assessing the
number of metastatic cells by clonogenic assay (35) (Supplementary Fig. S3B). 4T1/575
tumor-bearing mice survived significantly longer than mice with 4T1/irrelevant cells
supporting previously published work (36). Tumor-bearing mice treated with the inhibitors
trended towards fewer metastatic cells; however, the values were not statistically
significantly different. These results further confirm that HMGB1 enhances tumor
progression.
To determine if HMGB1 drives MDSC accumulation in vivo, tumor-bearing mice were
treated with a neutralizing HMGB1 mAb (2G7), and tumor-infiltrating MDSC and MDSC
from the blood and spleen were compared to MDSC in vehicle-treated tumor-bearing mice.
C57BL/6 mice were inoculated with the MC38 tumor on day 1 and 2G7 treatment was
started on day 10-13. Mice were sacrificed at a late stage of disease when their primary
tumors were approximately the same diameter, and total MDSC, monocytic MDSC, and
granulocytic MDSC levels in the blood, spleen, and infiltrating the tumors were determined
by flow cytometry (Fig. 6B). Total, monocytic, and granulocytic MDSC were reduced in the
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spleens, blood, and tumors of 2G7-treated mice with the exception of tumor-infiltrating
granulocytic MDSC. These decreases were not a secondary effect of reduced tumor size
since, at the time of analysis, the 2G7-treated and control-treated mice had similar-sized
primary tumors. MDSC were similarly reduced in the blood of A Box-treated tumor-bearing
mice. These results indicate that in vivo, neutralization of HMGB1 reduces the accumulation
of MDSC in tumor-bearing mice.
Tumors from the HMGB1 mAb-treated (2G7) and isotype control-treated mice of Fig. 6
were assessed by immunohistochemistry for the presence of CD3+ T cells (Supplementary
Fig. 4). Both types of tumors contained few T cells; however, there was a trend towards
more CD3+ cells in the tumors of 2G7-treated mice.
HMGB1 down-regulates T cell expression of L-selectin
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MDSC also impair T cell immunity by perturbing the homing of naive T cells to lymph
nodes where they could become activated. To enter lymph nodes T cells must first be
tethered via L-selectin (CD62L) to the walls of high endothelial venules (HEV) so they can
extravasate from the bloodstream. Our previous in vitro studies showed that MDSC reduce
T cell levels of L-selectin through their constitutive expression of ADAM17 (a disintegrin
and metalloproteinase domain 17), an enzyme that cleaves the ectodomain of L-selectin (4).
Subsequent in vivo vital imaging studies showed that T cells with reduced expression of Lselectin do not enter HEVs (J. Muhich, S. Ostrand-Rosenberg, S. Abrams, and S. Evans,
unpublished). To determine if HMGB1 impacts MDSC-mediated down-regulation of T cellexpressed L-selectin, A Box and control-treated mice were sacrificed 29 days after tumor
inoculation and circulating CD45+CD3+CD4+ and CD45+CD3+CD8+ T cells were analyzed
for L-selectin by flow cytometry (Fig. 7A). Circulating CD4+ and CD8+ T cells from tumorfree mice were controls for normal L-selectin expression. L-selectin was reduced in CD4+
and CD8+ T cells of tumor-bearing vehicle-treated mice, while A box-treatment partially
restored L-selectin expression (Fig. 7B). To confirm that HMGB1 acts on MDSC to reduce
L-selectin, Gr1+CD11b+ cells from tumor-free and tumor-bearing mice were treated for
zero, two, or four hours with HMGB1 or ethyl pyruvate, respectively. The cells were then
stained with mAbs to Gr1, CD11b, and ADAM17, and the gated Gr1+CD11b+ cells were
analyzed for plasma membrane expression of ADAM17 (Fig. 7C). HMGB1-treated
Gr1+CD11b+ cells from tumor-free mice expressed more ADAM17, while ethyl pyruvatetreated MDSC from tumor-bearing mice had less ADAM17, as compared to vehicle-treated
cells. These observations indicate that plasma membrane ADAM17 turns-over on MDSC
and that HMGB1 contributes to the down-regulation of L-selectin on T cells by sustaining
MDSC expression of ADAM17.

Discussion
The DAMP and alarmin HMGB1 is released by many tumor cells, is elevated in the serum
of many cancer patients (37), and is recognized as an enhancer of tumor progression by its
direct action on tumor cells (9, 10, 28). The studies reported here identify MDSC, along with
tumor cells and macrophages, as producers of HMGB1. The observed decrease in MDSC of
tumor-bearing mice following treatment with HMGB1 inhibitors, combined with the in vitro
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mechanistic studies demonstrate that HMGB1 (i) promotes the differentiation of MDSC
from bone marrow progenitor cells; (ii) increases MDSC-macrophage crosstalk and MDSC
production of IL-10; and (iii) increases MDSC-mediated down-regulation of L-selectin on
naive T cells. These findings support the conclusion that HMGB1 contributes to the
elevation and suppressive potency of MDSC in tumor-bearing mice, and identify a new proinflammatory mediator that regulates MDSC.
HMGB1 is likely to activate and drive MDSC because it induces, chaperones, and/or
enhances the activity of several pro-inflammatory molecules that regulate MDSC. For
example, IL-1β drives MDSC accumulation and T cell suppressive activity (33, 38) and is
induced by HMGB1 (14). Complexes of HMGB1 and IL-1β have increased proinflammatory activity relative to either molecule alone (39). HMGB1 also enhances the proinflammatory activity of IL-6 (40), TNFα (14), and prostaglandin E2 (41), three other proinflammatory mediators that drive MDSC (24, 34, 42, 43). Although neutralization of
HMGB1 significantly down-regulates MDSC suppressive activity, it does not globally
neutralize MDSC, most likely because the multiple pro-inflammatory mediators that drive
MDSC are redundant and can also be regulated by molecules other than HMGB1.

NIH-PA Author Manuscript

HMGB1 is known to facilitate tumor progression by co-opting other immune cells and by
directly affecting tumor cell growth (9, 10, 28). It increases the accumulation of T regulatory
cells and diverts type 1 T helper cells to a pro-tumor type 2 phenotype (36, 44). HMGB1
also acts directly on tumor cells to enhance tumor progression by binding to tumor cellexpressed RAGE. Many tumor cells express RAGE (45), and the binding of HMGB1 to
RAGE promotes tumor cell autophagy, inhibits tumor cell apoptosis, and increases tumor
cell invasiveness (46, 47). Collectively these effects produce an immune suppressive and
pro-tumor environment. MDSC contribute to tumor growth through their immune
suppressive mechanisms. However, their elimination may not be sufficient for tumor
rejection, and active immunization of T cells and/or repolarization of macrophages to a M1like phenotype may also be required (17). The studies reported here demonstrate that
HMGB1 affects MDSC development and function. Since HMGB1 impacts tumor
progression through multiple mechanisms that act on both tumor cells and immune cells, its
effects on MDSC represent only one of its modes of action.
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Paradoxically, under some conditions HMGB1 facilitates the activation of tumor-reactive T
cells. HMGB1 facilitates dendritic cell maturation (48) and enhances DC-mediated antigen
presentation during chemotherapy and radiotherapy (49). In contrast to the pro-tumor effects
of HMGB1 which are thought to be transmitted through RAGE, the enhancement of DC
function requires the release of HMGB1 by dead tumor cells and is mediated through DCexpressed TLR4. Whether the in vivo pro-tumor or anti-tumor effects of HMGB1 balance
each other, or whether one dominates is unclear. However, the potential for HMGB1 to both
inhibit and promote anti-tumor immunity makes it difficult to evaluate whether
neutralization of HMGB1 will be beneficial or harmful.
The quantity of HMGB1 within different solid tumors differs significantly (see
Supplementary Table 1). MDSC, macrophages, tumor-infiltrating cells, and tumor cells
themselves all contribute to the amount of HMGB1 in the tumor microenvironment. Live

Cancer Res. Author manuscript; available in PMC 2015 October 15.

Parker et al.

Page 12

NIH-PA Author Manuscript

tumor cells secrete HMGB1, while necrotic tumor cells induced by suboptimal
vascularization and hypoxia release nuclear HMGB1. Because the quantity of tumorinfiltrating cells and the extent of vascularization and hypoxia differ in different types of
tumors, it is not unexpected that the quantity of HMGB1 within solid tumors does not
correlate with tumor mass.
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HMGB1 binds to both TLR4 and RAGE, and MDSC express both receptors (20, 50). TLR4
and RAGE signaling converges at NF-κB (9, 10, 28, 51), so that activation through either
receptor may produce similar effects. Previous studies demonstrated that MDSC production
of IL-10 is regulated by TLR4 (50). In the current report, the RAGE antagonist, A Box,
partially restores T cell expression of L-selectin, suggesting that this effect of MDSC may be
regulated through RAGE. The HMGB1 inhibitors ethyl pyruvate and glycyrrhizin reduced
MDSC production of IL-10 during MDSC-macrophage crosstalk and the differentiation of
MDSC from bone marrow progenitor cells, and ethyl pyruvate restored T cell activation in
the presence of MDSC. These reagents either bind exogenous HMGB1 (glycyrrhizin) or
inhibit NF-κB signaling (ethyl pyruvate) and therefore do not distinguish whether HMGB1
is acting through TLR4 or RAGE. Regardless of which receptor is utilized, HMGB1 is a
potent inducer of MDSC and immune suppression, and both its pro-tumor and anti-tumor
activities must be considered when designing cancer immunotherapies.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. HMGB1 is ubiquitously present in the tumor microenvironment, is secreted by MDSC,
and activates the NF-κB signaling pathway in MDSC
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A, 4T1, CT26, B78H1, AT3 and MC38 tumor cells were cultured in serum-free medium and
their supernatants assessed by western blot for secreted HMGB1. Lysates of wild type and
HMGB1-knocked-out MEF cells served as positive and negative controls. B, BALB/c 4T1induced Gr1+CD11b+ MDSC were obtained from the blood of tumor-bearing mice, stained
for Gr1 and CD11b to assess purity, and co-cultured with transgenic CD4+ (DO11.10) or
CD8+ (clone4) splenocytes. Splenocytes were activated with OVA or HA peptide for
DO11.10 and clone4 cells, respectively. T cell proliferation was measured by [3H]
thymidine incorporation. Data are expressed as cpm of triplicate cultures. C, LPS-treated
and untreated macrophages and MDSC, and excised, dissociated tumors of BALB/c (4T1,
CT26) and C57BL/6 (B78HI, AT3, MC38) mice were cultured overnight in serum-free
medium. Resulting supernatants were assessed by western blot for HMGB1. D, Leukocytes
from tumor-free BALB/c mice were treated with or without HMGB1 and stained for Gr1,
CD11b, and pNF-κB. Gr1+CD11b+ cells were gated and analyzed for pNF-κB. Data are
from one of three, two, three, and three independent experiments for panels A, B, C, and D,
respectively.
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Figure 2. HMGB1 drives the differentiation of MDSC from bone marrow progenitor cells

Bone marrow cells were harvested from the femurs of healthy BALB/c mice and cultured
with IL-6 and GM-CSF with or without ethyl pyruvate, glycyrrhizin, or vehicle. After four
days of culture, the absolute number of MDSC was determined. A, HMGB1 western blot of
supernatants of bone marrow cultures. B, Gating logic of Gr1midCD11b+ MDSC from precultured and post-cultured bone marrow cells. C, Absolute number of Gr1midCD11b+
MDSC in the bone marrow cultures after incubation with ethyl pyruvate or glycyrrhizin. D,
MDSC generated in the bone marrow cultures were assessed for suppressive activity against
antigen-specific MHC-restricted transgenic CD4+ and CD8+ T cells. E, Bone marrow cells
were cultured under MDSC differentiation conditions (GM-CSF+IL-6) ± ethyl pyruvate
(EP) and analyzed for the percent of c-kit+ (CD117+) progenitor cells. p values were
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obtained by Student's t test. Data are from one of three and two independent experiments for
panels A-C and D-E, respectively.
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Figure 3. HMGB1 contributes to the ability of MDSC to suppress antigen-driven T cell
activation

Splenocytes from CD4+ DO11.10 TcR or CD8+ clone4 TcR transgenic mice were cocultured with irradiated 4T1-induced MDSC from BALB/c mice and cognate peptide (OVA
or HA peptide for DO11.10 and clone 4 T cells, respectively). A, T cell proliferation was
measured by [3H]-thymidine incorporation in the presence of titered amounts of ethyl
pyruvate or vehicle control. B, Ethyl pyruvate does not directly affect T cell activation.
Transgenic DO11.10 and clone4 T cells were activated with cognate peptide in the presence
of titered amounts of ethyl pyruvate. Data are from one of two independent experiments. p
values were obtained by Student's t test comparing ethyl pyruvate treated samples versus the
respective diluent control samples.
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Figure 4. HMGB1 increases MDSC production of IL-10 and MDSC-macrophage crosstalk

A, Co-cultures of 4T1-induced BALB/c MDSC and macrophages from tumor-free mice
were incubated with or without ethyl pyruvate or glycyrrhizin, and the supernatants were
assayed by ELISA for IL-10. B, MDSC from 4T1-tumor-bearing BALB/c and BALB/c
IL-10−/− mice and peritoneal macrophages from tumor-free BALB/c mice were co-cultured
and the supernatants were assayed by ELISA for IL-10. ND indicates non-detectable levels
of protein. Data are from one of six and three independent experiments for panels A and B,
respectively. p values were obtained by single-factor ANOVA.
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Figure 5. HMGB1 facilitates down-regulation of IL-6 and MDSC production of IL-1β, but does
not alter MDSC-mediated down-regulation of macrophage production of IL-12
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Co-cultures of 4T1-induced BALB/c MDSC and macrophages from tumor-free mice were
incubated with or without ethyl pyruvate or glycyrrhizin and the supernatants were assayed
by ELISA for IL-12, IL-6, and IL-1β. ND indicates non-detectable levels of protein. Data
are from one of four, five, and two independent experiments for IL-12, IL-6, and IL-1β,
respectively. p values were obtained by Student's t test.
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Figure 6. Tumor-bearing mice treated with mAbs to HMGB1 or with A Box have reduced levels
of MDSC
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A, C57BL/6 and BALB/c mice were inoculated s.c. with 5 x 105 MC38 colon carcinoma
cells or in the mammary fat pad with 7 x 103 4T1 mammary carcinoma cells, respectively.
Mice were given recombinant A box (300μg/mouse) or vehicle (PBS) three times per week
starting when tumors were first palpable (day 7-9 post inoculation). p values were obtained
by log rank test. B, C57BL/6 mice were inoculated as in panel A. Treatment with 2G7 (5μg/
200μl/mouse, 3x/week), irrelevant IgG, or A Box was started on day 10-13 when tumors
were first palpable. Treatment was terminated on day 45 and blood leukocytes were
analyzed by flow cytometry for total (Gr1+CD11b+), monocytic (MO;
CD11b+Ly6G-Ly6C+), and granulocytic (PMN; CD11b+Ly6G+Ly6C−) MDSC. Mice were
sacrificed on day 50 when their tumors were approximately the same size, and spleen and
tumor-infiltrating leukocytes (CD45+ cells) were analyzed by flow cytometry. n = 7 (blood,
control-treated for 2G7), 4 (A Box, PBS-treated), 6 (tumor-infiltrating and spleen, controltreated; blood, 2G7-treated), 4 (tumor-infiltrating and spleen, 2G7-treated), and 4 (A Boxtreated) mice/group. Data for 2G7 and their control-treated mice are pooled from two
independent experiments; data for A Box and their control-treated mice are from a single
experiment.
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Figure 7. HMGB1 down-regulates T cell expression of L-selectin
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A, Twenty-nine days after tumor inoculation the MC38 tumor-bearing mice from figure 6A
were sacrificed and blood leukocytes were analyzed by flow cytometry for L-selectin
expression and compared to blood leukocytes from tumor-free C57BL/6 mice.
Representative histograms showing L-selectin expression from gated CD45+CD3+CD4+ and
CD45+CD3+CD8+ T cells from tumor-free, A box-treated, or control-treated (PBS)
C56BL/6 tumor-bearing mice. B, Average percent ± SD of CD45+CD3+CD4+ or
CD45+CD3+CD8+ T cells expressing L-selectin. n= 5 mice/group (PBS-treated and tumorfree groups); n= 3 mice/group (A Box-treated group). p values were obtained by Student's t
test. Data are from one of two independent experiments. C, Gr1+CD11b+ cells from tumorfree (left-hand panels) or tumor-bearing (right-hand panels) mice were incubated in vitro for
zero, two, or four 4 hours with exogenous HMGB1 (left-hand panels) or ethyl pyruvate
(right-hand panels), and stained for Gr1, CD11b, and ADAM17. Gated Gr1+CD11b+ cells

Cancer Res. Author manuscript; available in PMC 2015 October 15.

Parker et al.

Page 24

were analyzed for ADAM17 expression. Graphs represent MCF of ADAM17 on
Gr1+CD11b+ cells. Data are representative of three independent experiments.
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